Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: Why still at the bench level?

European Journal of Clinical Pharmacology

Volumn 70, Issue 3, 2014, Pages 253-260

  Kodidela, Sunitha ^a   Suresh Chandra, Pradhan ^a   Dubashi, Biswajit ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Acute lymphoblastic leukemia; Methotrexate; Personalized medicine; Pharmacogenetics; Polymorphisms

Indexed keywords

ANTIMETABOLITES, ANTINEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; METHOTREXATE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84894475524     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1623-4     Document Type: Article

References (51)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society. Available from http://www.cancer.org/acs/groups/ content@epidemiologysurveilance/documents/document/acspc-029771.
2. Kulkarni KP, Arora RS, Marwaha RK (2011) Survival outcome of childhood acute lymphoblastic leukemia in India: a resource-limited perspective of more than 40 years. J Pediatr Hematol Oncol 33:475-479. doi: 10.1097/MPH. 0b013e31820e7361
3. Schrappe M, Hunger SP, Pui C-H et al (2012) Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 366:1371-1381. doi: 10.1056/NEJMoa1110169
4. Smith M, Arthur D, Camitta B et al (1996) Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 14:18-24
5. Schultz KR, Pullen DJ, Sather HN et al (2007) Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 109:926-935. doi: 10.1182/blood-2006-01- 024729
6. Pui C-H, Sandlund JT, Pei D et al (2004) Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104:2690-2696. doi: 10.1182/blood-2004-04-1616
7. Szczepański T, Orfão A, van der Velden VH et al (2001) Minimal residual disease in leukaemia patients. Lancet Oncol 2:409-417
8. Conter V, Bartram CR, Valsecchi MG et al (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206-3214. doi: 10.1182/blood-2009-10-248146
9. Borowitz MJ, Devidas M, Hunger SP et al (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 111:5477-5485. doi: 10.1182/blood-2008-01-132837
10. Estey EH, Appelbaum FR (eds) (2012) Leukemia and related disorders. Integrated treatment approaches series. Human Press, New York
11. Galivan J (1980) Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 17:105-110
12. McGuire JJ, Bertino JR (1981) Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem 38 Spec No[Pt 1]:19-48
13. Genestier L, Paillot R, Quemeneur L et al (2000) Mechanisms of action of methotrexate. Immunopharmacology 47:247-257
14. Szeto DW, Cheng YC, Rosowsky A et al (1979) Human thymidylate synthetase - III. Effects of methotrexate and folate analogs. Biochem Pharmacol 28:2633-2637
15. Chan ESL, Cronstein BN (2002) Molecular action of methotrexate in inflammatory diseases. Arthritis Res 4:266-273
16. Schmiegelow K (2009) Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 146:489-503. doi: 10.1111/j.1365-2141.2009. 07765.x
17. Davidsen ML, Dalhoff K, Schmiegelow K (2008) Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 30:831-849. doi: 10.1097/MPH.0b013e3181868570
18. Gorlick R, Goker E, Trippett T et al (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041-1048. doi: 10.1056/NEJM199610033351408
19. Chango A, Emery-Fillon N, de Courcy GP et al (2000) A polymorphism (80G- > A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 70:310-315. doi: 10.1006/mgme.2000.3034
20. Laverdière C, Chiasson S, Costea I et al (2002) Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100:3832-3834. doi: 10.1182/blood.V100.10.3832
21. Leyva-Vázquez MA, Organista-Nava J, Gómez-Gómez Y et al (2012) Polymorphism G80A in the reduced folate carrier gene and its relationship to survival and risk of relapse in acute lymphoblastic leukemia. J Investig Med Off Publ Am Fed Clin Res 60:1064-1067. doi: 10.231/JIM. 0b013e31826803c1
22. Shimasaki N, Mori T, Samejima H et al (2006) Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 28:64-68. doi: 10.1097/01.mph.0000198269.61948.90
23. Radtke S, Zolk O, Renner B et al (2013) Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121:5145-5153. doi: 10.1182/blood-2013-01-480335
24. Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S et al (2007) Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol 86:609-611. doi: 10.1007/s00277-007-0274-x
25. Goldman ID, Matherly LH (1985) The cellular pharmacology of methotrexate. Pharmacol Ther 28:77-102
26. Olsen EA (1991) The pharmacology of methotrexate. J Am Acad Dermatol 25:306-318
27. König J, Cui Y, Nies AT, Keppler D (2000) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278:G156-G164
28. Van de Steeg E, van der Kruijssen CMM, Wagenaar E et al (2009) Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos Biol Fate Chem 37:277-281. doi: 10.1124/dmd.108.024315
29. Treviño LR, Shimasaki N, Yang W et al (2009) Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol Off J Am Soc Clin Oncol 27:5972-5978. doi: 10.1200/JCO.2008.20.4156
30. Ramsey LB, Panetta JC, Smith C et al (2013) Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 121:898-904. doi: 10.1182/blood-2012-08-452839
31. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J et al (2011) Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57:612-619. doi: 10.1002/pbc.23074
32. Danenberg PV (1977) Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473:73-92
33. Horie N, Aiba H, Oguro K et al (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20:191-197
34. Kaneda S, Nalbantoglu J, Takeishi K et al (1990) Structural and functional analysis of the human thymidylate synthase gene. J Biol Chem 265:20277-20284
35. Kawakami K, Salonga D, Park JM et al (2001) Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res Off J Am Assoc Cancer Res 7:4096-4101
36. Wang W, Marsh S, Cassidy J, McLeod HL (2001) Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res 61:5505-5510
37. Krajinovic M, Costea I, Chiasson S (2002) Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 359:1033-1034. doi: 10.1016/S0140-6736(02)08065-0
38. Krajinovic M, Costea I, Primeau M et al (2005) Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J 5:374-380. doi: 10.1038/sj.tpj.6500332
39. Lauten M, Asgedom G, Welte K et al (2003) Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica 88:353-354
40. Pietrzyk JJ, Bik-Multanowski M, Skoczen S et al (2011) Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL. Leuk Res 35:1464-1466. doi: 10.1016/j.leukres.2011.04.007
41. Frosst P, Blom HJ, Milos R et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113. doi: 10.1038/ng0595-111
42. Weisberg I, Tran P, Christensen B et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169-172. doi: 10.1006/mgme.1998. 2714
43. Aplenc R, Thompson J, Han P et al (2005) Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 65:2482-2487. doi: 10.1158/0008-5472.CAN-04-2606
44. Tanaka Y, Manabe A, Nakadate H et al (2013) Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients. Leuk Lymphoma. doi: 10.3109/10428194.2013.825902
45. Chiusolo P, Reddiconto G, Farina G et al (2007) MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res 31:1669-1674. doi: 10.1016/j.leukres.2007.03.028
46. Li W, Fan J, Hochhauser D et al (1995) Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 92:10436-10440
47. Hochhauser D, Schnieders B, Ercikan-Abali E et al (1996) Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst 88:1269-1275
48. Costea I, Moghrabi A, Krajinovic M (2003) The influence of cyclin D1 (CCND1) 870A > G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics 13:577-580. doi: 10.1097/01.fpc.0000054123.14659.57
49. Costea I, Moghrabi A, Laverdiere C et al (2006) Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 91:1113-1116
50. Dulucq S, St-Onge G, Gagné V et al (2008) DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood 111:3692-3700. doi: 10.1182/blood-2007-09-110593
51. Al-Shakfa F, Dulucq S, Brukner I et al (2009) DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. Clin Cancer Res Off J Am Assoc Cancer Res 15:6931-6938. doi: 10.1158/1078-0432.CCR-09-0641